Clinical Trial Update: Study Of Two Dosing Regimens Of PF-04937319 Compared To An Approved Agent (Sitagliptin) In Patients With Type 2 Diabetes [Phase 1]

View source ↗

Summary

A Phase 1 trial comparing two dosing regimens of PF-04937319 with Sitagliptin in adults with Type 2 Diabetes Mellitus; results were posted in 2016.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Type 2 Diabetes Mellitus

Drugs mentioned

• PF-04937319
• Sitagliptin (sitagliptin)

Snippet

Sponsor: Pfizer | Conditions: Type 2 Diabetes Mellitus | Phase 1 | Status: COMPLETED | Results posted: 2016-09-27